ON012380: A Non-Atp Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs

doi 10.21236/ada510718
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Defense Technical Information Center

Related search

A Non-Atp-Competitive Inhibitor of BCR-ABL Overrides Imatinib Resistance

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2005English

In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells

Cancer Research
Cancer ResearchOncology
2006English

Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I

Blood
BiochemistryImmunologyCell BiologyHematology
2008English

NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2011English

Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias

PLoS ONE
Multidisciplinary
2014English

Coexistence of AML1/RUNX1 and BCR-ABL Point Mutations in an Imatinib-Resistant Form of CML

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

In Vivo Imaging of BCR-Abl Overexpressing Tumors With a Radiolabeled Imatinib Analog as an Imaging Surrogate for Imatinib

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2011English

Detection of Single Nucleotide Insertion of BCR/ABL Region in Imatinib-Resistant Human Myelogenous Leukemia SR-1 Cells

Experimental & Molecular Medicine
2005English

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy